Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field

Executive Summary

Scrip spoke with five companies about their places in the crowded IO field in which big pharma and small biotech firms alike are seeking the best options for harnessing the immune system to fight cancer.

Advertisement

Related Content

Pipeline Watch: Evolocumab, Roxadustat And SB-204, Top-line Results
Tocagen Aims Double Barrels At Glioma
Wait For Me: AstraZeneca’s Durvalumab Gets Its Turn At The FDA
Xencor's Coming Share Issue To Help Fund Immuno-Oncology Pipeline
Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition
Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
Startups Stand Out As 13 Biotechs Raise More Than $409m
Is the Biotech IPO Window Closing?
Flexus flips IDO inhibitors to Bristol-Myers for up to $1.25bn

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel